Inflammatory Bowel Disease

Top Story

Celgene halts mongersen trials in Crohn’s disease

October 20, 2017

Celgene announced it has discontinued two trials of drug candidate GED-0301 (mongersen) in Crohn’s disease due to disappointing results.

The company said it decided to stop the phase 3 REVOLVE trial (CD-002) and the extension trial (SUSTAIN, CD-004) based on the Data Monitoring Committee’s recommendation in October following an interim analysis of observed risks and benefits. A press release noted this analysis showed “no meaningful safety imbalances.”

Meeting News

Novel blood test accurately assesses mucosal healing across Crohn’s subtypes

October 18, 2017
ORLANDO — A novel multi-biomarker serum test accurately evaluated mucosal healing across different subtypes of Crohn’s disease based on disease location…
Meeting News

IBD increasing in developing nations, stabilizing in the West

October 18, 2017
ORLANDO — Inflammatory bowel disease has become a global disease since the turn of the century, with incidence plateauing in the West, but increasing in the…
Meeting News

Dose-escalation in IBD after CDI does not increase adverse outcomes risk

October 17, 2017
ORLANDO — Initiating immunosuppressive medication following treatment for Clostridium difficile infection was not correlated with adverse clinical outcomes in…
More Headlines »
Advertisement
Advertisement